Moreover, western blot assay revealed increase in H3K4me3 and PLK2 protein levels, concurrent with the inhibition of the PI3K/AKT/mTOR pathway, as evidenced by reduced expressions of p110 α, p-AKT (Ser 473), and p-mTOR (Ser 2448) in AS-8351 treatment groups compared to vehicle groups in NPC PDX models and AGS-EBV cell xenografts (Fig. 8f). The gene discussed is PLK2; the disease is nasopharyngeal carcinoma.